Navigation Links
Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms
Date:3/31/2008

At two years, Company's TAXUS(R) and PROMUS(TM) Stents demonstrate positive

and similar outcomes

NATICK, Mass. and CHICAGO, March 31 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed positive two-year results from Abbott's prospective, randomized (3:1), single blind, non-inferiority SPIRIT II Trial comparing the safety and efficacy of the XIENCE(TM) V (PROMUS(TM)) Everolimus-Eluting Coronary Stent and Boston Scientific's worldwide market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System ("TAXUS Stent") in 300 patients in Europe. The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. Boston Scientific is the only company offering two distinct drugs on two deliverable platforms - the TAXUS and PROMUS Stents. The results were presented today at the SCAI Annual Scientific Sessions in Partnership with the ACC/i2 Summit in Chicago by Professor Patrick Serruys, M.D., Ph.D., Chief of Interventional Cardiology, Thoraxcenter-Erasmus University Rotterdam, The Netherlands, and the SPIRIT II Principal Investigator.

At two years, results from the SPIRIT II trial demonstrated no numerical difference between the XIENCE V (PROMUS) Stent and the TAXUS Stent in their angiographic outcomes, nor were there statistically significant differences in the clinical outcomes. The cardiac death rate for the XIENCE V (PROMUS) Stent was 0.5 percent and for the TAXUS Stent was 1.4 percent (p=0.45). Myocardial infarction (MI) rates for the XIENCE V (PROMUS) Stent and the TAXUS Stent were 2.8 percent and 5.5 percent (p=0.29), respectively. Ischemia-driven target lesion revascularization (ID-TLR) rates were comparable, at 3.8 percent for the XIENCE V (PROMUS) Stent and 6.8 percent for the TAXUS Stent (p=0.33). Major adverse cardiac events (MACE) rates comprised of cardiac death, all MI and ID-TLR were also comparable, at 6.6 percent for the XIENCE V (PROMUS) Stent and 11.0 percent for the TAXUS Stent (p=0.31).

Stent thrombosis rates at two years using the Academic Research Consortium (ARC) definite/probable definition were low for both the XIENCE V (PROMUS) Stent (0.9%) and the TAXUS Stent (1.4%). Angiographic outcomes showed numerically equivalent late loss, with 0.33 mm for XIENCE V (PROMUS) and 0.34 mm for TAXUS (p=0.60). In-stent binary restenosis rates at two years were also comparable for the XIENCE V (PROMUS) Stent and the TAXUS Stent (2.1% vs. 2.9%, p=1.0).

"Boston Scientific's two DES platforms - the TAXUS and PROMUS Stents - both performed extremely well in the SPIRIT II Trial out to two years," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "The data, once again, demonstrated impressive safety and efficacy profiles with low stent thrombosis rates and similar clinical outcomes. We look forward to future data from the SPIRIT Clinical Trial Program as well as from our PROENCY Registries in Europe and the United States - the first to observe different 'Olimus-eluting coronary stents in a real-world setting."

In February, Boston Scientific announced that the first patient had been enrolled in its PROENCY (PROMUS(TM), ENdeavor(R) and CYpher(R)) European Registry. The registry will collect real-life clinical outcome data for the PROMUS Stent and compare them with data from Johnson & Johnson's Cypher(R) Sirolimus-Eluting Stent and Medtronic's Endeavor(R) Zotarolimus-Eluting Stent in patients in routine clinical practice. A U.S. PROENCY Registry is expected to begin enrolling patients in July and complete enrollment by the end of 2008.

The XIENCE(TM) V (PROMUS) Stent is currently pending approval by the U.S. Food and Drug Administration (FDA), which is expected to occur in the first half of 2008. Upon FDA approval of the PROMUS Stent, Boston Scientific will immediately make it available for sale in the United States.

The PROMUS Stent is an investigational device in the U.S. and not yet approved for sale. The PROMUS Stent is currently for sale in Europe and certain other international markets. TAXUS and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of the Abbott Laboratories group of companies. The SPIRIT Clinical Program is sponsored by Abbott.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, product performance, competitive offerings, procedural volume, overall market size and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
3. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
4. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
9. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
10. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
11. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, ... QGEN ; Frankfurt Prime Standard: QIA) today announced that the ... Therawis Diagnostics GmbH to develop and commercialize predictive assays in ... PITX2 as a marker to predict effectiveness of anthracycline treatment ... "We are pleased to partner with Therawis, which developed ...
(Date:5/25/2016)... NEW YORK , May 25, 2016 ... Device Market Size, Share, Development, Growth and Demand Forecast ... Insulin Syringe, Insulin Pump and Others)" published by P&S ... valued at $9,998.3 million in 2015, and it is ... 2016-2022. Based on type, the insulin pump segment is ...
(Date:5/25/2016)... Digital Health Dialog, LLC dba EngagedMedia ... US Patent and Trademark Office of U.S. Patent ... for electronic opt-­in and processing of discount coupons ... compliance and otherwise. Logo - http://photos.prnewswire.com/prnh/20160524/371583LOGO ... "Our technology allows for individuals to opt­-in to ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... , ... North Cypress Medical Center hosted its 9th Annual Spring ... the help of community partners, the event organizers raised $45,000 for the Lone ... members and their families through health, wellness, and therapeutic support. , A special ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age Management ... Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the MIAMI ... member of the Institute for Functional Medicine. , He also heads up FITTLab, the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the ... bunionette) treatment was more than humbled by customer demand over the Mother’s Day Weekend ... mid sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes ...
(Date:5/26/2016)... ... May 26, 2016 , ... A health conscious snack ... The Dough Bar, has ignited an undeniable buzz in the protein product community ... not just any doughnut.  These doughnuts are packed with 11 grams of protein and ...
(Date:5/26/2016)... ... 2016 , ... Metcalf & Associates’ Maureen Metcalf ... in leading technology and human resources operations for health care, education, banking, and ... featured on Metcalf’s VoiceAmerica radio show , Innovative Leaders Driving Thriving Organizations. ...
Breaking Medicine News(10 mins):